Volume 85, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We report an unusual case of visceral leishmaniasis occurring in a patient from Sichuan China. The patient presented with a remitting fever, anemia, and pancytopenia. The case was confirmed as visceral leishmaniasis by microscopical detection of the species amastigote in bone marrow aspirate. The patient was treated with 10 mg/kg/day of sodium stibogluconate for 5 days, with no therapeutic response. As a result, the patient was treated with liposomal amphotericin B (LAB) at 10 mg/day as an initial dosage. After treatment with an increasing drug dosage for 7 days, acute renal injury was evident as indicated by increased serum creatinine and urea nitrogen. LAB administration was discontinued until serum creatinine and serum urea nitrogen regressed on Day 15. Two maintenance treatments of 100 mg/day LAB were given on Days 19 and 26 (total 870 mg, 14.5 mg/kg). Bone marrow aspirate and clinical examination suggested total remission.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Zhang LP, Zhang FN, 2010. Epidemiological and clinical analysis of 166 kala-azar cases. Parasites Infect Dis 18: 181186.
    [Google Scholar]
  2. Killick-Kendrick R, 2010. Education is key to controlling visceral leishmaniasis. Bull World Health Organ 88: 1112.[Crossref]
    [Google Scholar]
  3. Mondal S, Bhattacharya P, Ali N, 2010. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919944.[Crossref]
    [Google Scholar]
  4. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F, 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet 377: 477486.[Crossref]
    [Google Scholar]
  5. Kang X, Liu Y, Liu K, Lu X, 2009. Human leishmaniasis: a retrospective clinical analysis of 86 patients. Chin J Infect Chemother 9: 241243.
    [Google Scholar]
  6. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref]
    [Google Scholar]
  7. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512.[Crossref]
    [Google Scholar]
  8. Thakur CP, 2001. A single high dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17: 6770.[Crossref]
    [Google Scholar]
  9. Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreño F, Pandey K, 2010. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83: 357364.[Crossref]
    [Google Scholar]

Data & Media loading...

  • Received : 12 Jul 2011
  • Accepted : 21 Sep 2011
  • Published online : 01 Dec 2011
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error